Thesis (M.A.)--Miami University, Dept. of History, 2005. / Title from first page of PDF document. Document formatted into pages; contains [1], iii, 89 p. : ill. Includes bibliographical references (p. 80-89).

Dissertação (mestrado)—Universidade de Brasília, Instituto de Química, 2016. / Submitted by Albânia Cézar de Melo (albania@bce.unb.br) on 2016-06-08T13:01:07Z No. of bitstreams: 1 2016_NathaliaSiqueiraAlmeida.pdf: 10329727 bytes, checksum: 8ac15e063817d1467f56b0d4f171b221 (MD5) / Approved for entry into archive by Raquel Viana(raquelviana@bce.unb.br) on 2016-06-15T10:47:39Z (GMT) No. of bitstreams: 1 2016_NathaliaSiqueiraAlmeida.pdf: 10329727 bytes, checksum: 8ac15e063817d1467f56b0d4f171b221 (MD5) / Made available in DSpace on 2016-06-15T10:47:39Z (GMT). No. of bitstreams: 1 2016_NathaliaSiqueiraAlmeida.pdf: 10329727 bytes, checksum: 8ac15e063817d1467f56b0d4f171b221 (MD5) / A validação de um método analítico é essencial para demonstrar que ele é adequado para um determinado uso e para garantir a qualidade e a confiabilidade estatística das medidas, dos cálculos envolvidos no processamento dos dados e dos resultados experimentais obtidos. Para que um novo método possa ser incorporado nas operações de rotina de um laboratório, devem ser apresentadas evidências objetivas e rastreáveis de que requisitos específicos, denominados figuras de mérito, estão sendo atendidos. No caso da identificação e quantificação de drogas de abuso, a maioria dos processos de validação envolve métodos analíticos que exigem o uso do padrão certificado do analito. Essa é uma grande dificuldade no Brasil, uma vez que o acesso a padrões certificados de drogas de abuso é ainda muito restrito. No presente projeto, comprimidos de ecstasy, contendo o 3,4-metilenodioximetanfetamina (MDMA), apreendidos pelo Polícia Federal, foram caracterizados e tiveram seu princípio ativo quantificado por dois métodos para a construção do perfil químico da droga. A cromatografia gasosa com detector por ionização em chama (CG-DIC), utilizada rotineiramente em laboratórios forenses, foi utilizada como método de referência para avaliação da ressonância magnética nuclear de hidrogênio (RMN de 1H), que é um método ainda pouco utilizado. Os dois métodos foram validados, atendendo todos os requisitos do sistema de gestão da qualidade do laboratório central de química forense da Polícia Federal, obtendo resultados considerados adequados para linearidade, precisão, exatidão, robustez, seletividade, limites de detecção e quantificação e estimativa da incerteza de medição. As amostras de ecstasy analisadas no trabalho correspondem a 25 apreensões da Polícia Federal, em 6 estados brasileiros, de 2011 a 2013, e foram divididas em 39 lotes. A análise por CG-DIC demonstrou que a pureza das amostras variou de 10,5 % a 77,0 % e alguns adulterantes foram identificados em 15 % dos lotes. Apesar dos resultados quantitativos dos dois métodos terem sido equivalentes, o RMN de 1H se mostrou mais eficiente e versátil ao realizar tanto a identificação inequívoca quanto a quantificação do analito em uma mesma análise, uma vez que dispensa o uso de padrão do analito e a construção de curvas analíticas. _______________________________________________________________________________________________ ABSTRACT / The validation of an analytical method is essential to demonstrate that it is suitable for a particular use and to ensure the quality and statistical reliability of the measures, the calculations involved in the data processing and the experimental results obtained. In order to incorporate a new method into the routine operations of a laboratory, must be presented objective and traceable evidences that specific requirements, called figures of merit, are being attended. Regarding identification and quantification of drugs of abuse, most of validation processes involve analytical methods that require the use of the analyte’s standard. Since the access to standards of drugs of abuse in Brazil is still very restricted, it brings a major difficulty to the validation process. In this project, ecstasy tablets containing 3,4-methylenedioxymethamphetamine (MDMA), seized by the Federal Police, have been characterized and had the active ingredient quantified by two methods to achieve chemical profiling information. The gas chromatography with flame ionization detector (GC-FID) method, routinely used in forensic laboratories, was used as reference for evaluating the proton nuclear magnetic resonance (1H-NMR) method, which is yet barely used. Both methods have been validated, complying with all requirements of the forensic chemistry central lab of Federal Police quality system, with suitable results for linearity, precision, accuracy, robustness, selectivity, limits of detection and quantification and estimation of measurement uncertainty. The ecstasy samples analyzed in this work correspond to 25 Federal Police seizures, performed between 2011 and 2013, in 6 Brazilian states, and were divided into 39 batches. GC-FID analysis showed that sample purity ranged from 10.5 % to 77.0 % and some contaminants have been identified in 15 % of the batches. Despite quantitative results of both methods were equivalent, the 1H-NMR was more efficient and versatile to accomplish unambiguous identification and quantification of the analyte in a single analysis, since it doesn’t require the use of analyte’s standard and the construction of calibration curves.

No description available.

No description available.

O N-metil- 3-4, metilenodioximetanfetamina (MDMA) ou ecstasy tem sido freqüentemente usado por jovens. Analisamos neste trabalho, dentro de uma perspectiva neuroimune, os efeitos da administração aguda de MDMA em parâmetros comportamentais, neuroendócrinos, hematatológicos e imunes de camundongos Balb/C, usando para esta última finalidade um modelo de asma experimental. O MDMA produziu: 1- aumento diferencial da atividade locomotora nas diferentes zonas do campo aberto; aumento na locomoção total e diminuição da atividade exploratória no hole-board; aumento da porcentagem de entradas e da taxa de permanência nos braços abertos do LCE; aumento no tempo gasto na caixa de saída e diminuição do número de acessos de risco em uma caixa de exposição a um predador; 2- aumento dos níveis séricos de corticoterona; 3- aumento dos níveis de noradrenalina no estriado e córtex frontal, aumento nos níveis de dopamina e de DOPAC no estriado, diminuição dos níveis de DOPAC corticais, aumento de 5-HT e 5-HIAA no estriado, diminuição dos níveis de 5- HIAA e do turnover de serotonina no hipotálamo e diminuição do \"turnover\" de dopamina no estriado e córtex frontal; 4- alteração na migração de leucócitos em camundongos alérgicos com diminuição da porcentagem de linfócitos e monócitos circulantes, diminuição do número de granulócitos no lavado bronco alveolar (LBA), efeitos estes que foram revertidos pelo pré-tratamento com RU-486; 5 redução da expressão de L-selectinas por monócitos e tendência de redução da expressão de L -selectinas por neutrófilos no pulmão; 6- diminuição das produções espontâneas de IL-4, IL-5 e IL-10 e de IL-4 em cultura estimulada com LPS; 7- redução da contração da traquéia isolada de animais alérgicos e 8- redução da desgranulação dos mastócitos em brônquios intrapulmonares. Sugeriu-se que o estresse/ansiedade induzidos pelo MDMA tenham ativado o eixo HHA e/ou do sistema nervoso autonômico simpático dos camundongos, alterando a resposta imune dos mesmos na vigência de um modelo de asma. A inflamação alérgica pulmonar desponta, assim, como importante ferramenta para o entendimento da ação de drogas de abuso em processos neuroimunológicos. / The N-metil- 3-4, metilenodioximetanfetamina (MDMA) or ecstasy is a drug widely used amongst young people. This study was undertaken to analyze, under a neuroimmune perspective, the effects of acute MDMA administration on behavioral, neuroendocrine, hematological and immune parameters on Balb/C mice, using for the latter purpose the allergic lung inflammatory response model. It was observed that MDMA produced in mice: 1- a differential increase on total locomotion in the different open-field zones; an increase on total locomotion and a decrease on exploratory activity in the hole-board; an increase on both percentage of entrances and time spent on plus-maze open arms; an increase on time spent in the starting box and a decrease of risk assessments in a predator exposition box; 2- an increase in corticosterone serum levels; 3- an increase in striatal and frontal cortex noradrenaline levels, an increase in striatal dopamine and DOPAC levels, a decrease in cortical DOPAC levels, an increase in striatal 5-HT and 5-HIAA levels, a decrease in both 5-HIAA levels and 5-HT turnover rates in hypothalamus and a decrease in striatal and cortical dopamine \"turnover\" rates; 4- an alteration on leukocyte migration in allergic mice, i.e., decreased percentage of peripheral blood lymphocytes and monocytes, decreased number of granulocytes on bronchoalveolar lavage fluid ( LBA); these effects were reverted by previous RU-486 treatment; 5- a decrease in L-selectin expression by monocytes and a tendency towards a decrease in L-selectin expression by lung neutrophils; 6- a decrease on expontaneous production of IL-4, IL-5 e IL-10 and IL-4 in LPS-stimulated cultures; 7- a decrease in the contraction of allergic mice isolated trachea; and, 8- a decrease in bronchial mastocytes degranulation. It was suggested that MDMA-induced anxiety/stress symptoms increasing HHA-axis and/or the autonomic nervous system activities this leading to the immune changes observed presently in the allergic lung inflammation model of asthma used. This model, thus, emerges as a useful tool for the understanding of neuroimmune effects of drugs of abuse.

Hintergrund: In den letzten Jahren ist zunehmend deutlich geworden, dass Konsumenten von Ecstasy sich hinsichtlich Gebrauchsmuster und -kontext wie auch Spontanverlauf, Risiken und Konsequenzen von Konsumenten anderer legaler und illegaler Substanzen unterscheiden und möglicherweise eine recht eigenständige Gruppe darstellen. Diese eigenständige Gruppe wird im angelsächsischen Raum zum Teil auch als club drug user bezeichnet. Alarmierend waren die Vermutungen aus Voruntersuchungen, dass club drug-Konsumenten auch nach dem Konsum geringer Mengen von Ecstasy bemerkenswerte und möglicherweise überdauernde neurobiologische Veränderungen mit assoziierten kognitiven Beeinträchtigungen und Störungen aufzeigen. Dies stellt an sich eine mögliche Gefährdung der Konsumenten dar, zusätzlich wiederum können kognitive Veränderungen auch Einfluss nehmen auf den Verlauf des weiteren Suchtmittelkonsums und den Erfolg von Interventionen. Ziel: In der MAYA-Studie (Munich Assessment of Young Adults) werden an einer epidemiologischen Bevölkerungsstichprobe junger Erwachsener (Stichprobe A) sowie an einer klinischen Stichprobe von Ecstasy-Konsumenten (Stichprobe B) die Art und das Ausmaß kognitiver Störungen und Defizite in Abhängigkeit von Gebrauchsmustern und anderen Einflussfaktoren untersucht. Bei der Stichprobe A handelt es sich um ein Subsample der EDSPStudie. Zusätzlich zu den bereits erhobenen Charakterisierungen werden spezifische neurokognitive Maße (vor allem Aufmerksamkeit, Gedächtnis und exekutive Funktionen) und Fragebögen (Impulsivität, BDI, STAI etc.) erhoben. Die Probanden erhalten weiterhin ein Screening mit dem neu eingeführten Instrument WHO ASSIST (Alcohol, Smoking and Substance Involvement Screening Test). Wenn indiziert, wird eine Intervention im Sinne eines Motivational Enhancement durchgeführt. Initiale Auswirkungen werden in einem Telefoninterview sechs Wochen später überprüft. Ergebnisse: Die vorläufigen Ergebnisse beruhen auf einer Teilstichprobe. Insgesamt handelte es sich eher um Konsumenten mit geringgradigem bis moderaten Konsum. Dennoch ließen sich Unterschiede zwischen den Konsumentengruppen (Ecstasy, Cannabis, Alkohol) und den Nichtkonsumenten erkennen. Die Konsumenten von Ecstasy unterschieden sich am ausgeprägtesten von den Kontrollen. Die sich bisher abzeichnenden Unterschiede bei Aufmerksamkeit, Gedächtnis und exekutiven Funktionen scheinen bei der Gedächtnis- und Merkfähigkeit am ausgeprägtesten zu sein. Bei diesen vorläufigen Ergebnissen sind die Untersuchungsgruppen noch sehr heterogen und enthalten z.B. Probanden, die ihren Ecstasykonsum bereits wieder aufgegeben haben. / Introduction: In recent years it has become increasingly evident that ecstasy users represent a group distinct from users of other drugs. This is based on consumption patterns, context of use, development of use patterns and other factors. This group of users might be considered "club drug users", given the overlap, similarity of use patterns and consumptions within the class of club drugs. In recent neurobiological research, alarming results have been reported, indicating that persistent neurotoxic effects with concomitant cognitive problems may be induced by ecstasy consumption. Methods: In the Munich Assessment of Young Adults Study (MAYA) two samples of ecstasy users are investigated. Sample A is a sample of users drawn from an ongoing epidemiological longitudinal study of young adults in Munich. Sample B is an additional clinical sample. Both samples are characterized extensively and are neuropsychologically tested for attention, memory and executive functioning. A screening for harmful use is conducted with the German version of the WHO ASSIST (Alcohol, Smoking and Substance Involvement Screening Test). A Motivational Enhancement Intervention is applied when harmful use is detected. With a telephone interview the intervention's initial effect is assessed. Results: Initial results are based on a small sample. Use within the tested population is low to moderate. Still significant differences in attention, memory, and executive functioning could be detected with the current testing. Ecstasy users almost consistently showed the lowest cognitive functioning. The one difference is that ecstasy users were significantly faster in finger tapping and reaction. Note that the results are preliminary. The sample is heterogeneous, including both current and former users. Firmer results will be reported with the full sample size, allowing to further elucidate subgroups and interactions.

O N-metil- 3-4, metilenodioximetanfetamina (MDMA) ou ecstasy tem sido freqüentemente usado por jovens. Analisamos neste trabalho, dentro de uma perspectiva neuroimune, os efeitos da administração aguda de MDMA em parâmetros comportamentais, neuroendócrinos, hematatológicos e imunes de camundongos Balb/C, usando para esta última finalidade um modelo de asma experimental. O MDMA produziu: 1- aumento diferencial da atividade locomotora nas diferentes zonas do campo aberto; aumento na locomoção total e diminuição da atividade exploratória no hole-board; aumento da porcentagem de entradas e da taxa de permanência nos braços abertos do LCE; aumento no tempo gasto na caixa de saída e diminuição do número de acessos de risco em uma caixa de exposição a um predador; 2- aumento dos níveis séricos de corticoterona; 3- aumento dos níveis de noradrenalina no estriado e córtex frontal, aumento nos níveis de dopamina e de DOPAC no estriado, diminuição dos níveis de DOPAC corticais, aumento de 5-HT e 5-HIAA no estriado, diminuição dos níveis de 5- HIAA e do turnover de serotonina no hipotálamo e diminuição do \"turnover\" de dopamina no estriado e córtex frontal; 4- alteração na migração de leucócitos em camundongos alérgicos com diminuição da porcentagem de linfócitos e monócitos circulantes, diminuição do número de granulócitos no lavado bronco alveolar (LBA), efeitos estes que foram revertidos pelo pré-tratamento com RU-486; 5 redução da expressão de L-selectinas por monócitos e tendência de redução da expressão de L -selectinas por neutrófilos no pulmão; 6- diminuição das produções espontâneas de IL-4, IL-5 e IL-10 e de IL-4 em cultura estimulada com LPS; 7- redução da contração da traquéia isolada de animais alérgicos e 8- redução da desgranulação dos mastócitos em brônquios intrapulmonares. Sugeriu-se que o estresse/ansiedade induzidos pelo MDMA tenham ativado o eixo HHA e/ou do sistema nervoso autonômico simpático dos camundongos, alterando a resposta imune dos mesmos na vigência de um modelo de asma. A inflamação alérgica pulmonar desponta, assim, como importante ferramenta para o entendimento da ação de drogas de abuso em processos neuroimunológicos. / The N-metil- 3-4, metilenodioximetanfetamina (MDMA) or ecstasy is a drug widely used amongst young people. This study was undertaken to analyze, under a neuroimmune perspective, the effects of acute MDMA administration on behavioral, neuroendocrine, hematological and immune parameters on Balb/C mice, using for the latter purpose the allergic lung inflammatory response model. It was observed that MDMA produced in mice: 1- a differential increase on total locomotion in the different open-field zones; an increase on total locomotion and a decrease on exploratory activity in the hole-board; an increase on both percentage of entrances and time spent on plus-maze open arms; an increase on time spent in the starting box and a decrease of risk assessments in a predator exposition box; 2- an increase in corticosterone serum levels; 3- an increase in striatal and frontal cortex noradrenaline levels, an increase in striatal dopamine and DOPAC levels, a decrease in cortical DOPAC levels, an increase in striatal 5-HT and 5-HIAA levels, a decrease in both 5-HIAA levels and 5-HT turnover rates in hypothalamus and a decrease in striatal and cortical dopamine \"turnover\" rates; 4- an alteration on leukocyte migration in allergic mice, i.e., decreased percentage of peripheral blood lymphocytes and monocytes, decreased number of granulocytes on bronchoalveolar lavage fluid ( LBA); these effects were reverted by previous RU-486 treatment; 5- a decrease in L-selectin expression by monocytes and a tendency towards a decrease in L-selectin expression by lung neutrophils; 6- a decrease on expontaneous production of IL-4, IL-5 e IL-10 and IL-4 in LPS-stimulated cultures; 7- a decrease in the contraction of allergic mice isolated trachea; and, 8- a decrease in bronchial mastocytes degranulation. It was suggested that MDMA-induced anxiety/stress symptoms increasing HHA-axis and/or the autonomic nervous system activities this leading to the immune changes observed presently in the allergic lung inflammation model of asthma used. This model, thus, emerges as a useful tool for the understanding of neuroimmune effects of drugs of abuse.

Post-traumatic stress disorder (PTSD) is a disabling condition that afflicts 1-10% of the general population, with twice as high lifetime prevalence for women than men. Treatments exist, but none have proven reliable and consistent efficacy. A large minority of patients remain treatment-resistant despite undergoing several different types of treatment over extended periods of time. Recently completed studies in the U.S. and in Switzerland have demonstrated the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treatment-resistant PTSD. One of the major problems of treating PTSD is the patients’ fear state and inability to form a therapeutic alliance. Both these issues can be facilitated through administration of MDMA; the psychological effects - such as heightened empathy, increased openness and diminished anxiety – seem well-suited for therapeutic purposes. The rationale behind treating PTSD with MDMA has been indicated in neuroimaging studies; MDMA affects some of the neural structures altered in patients with PTSD, most notably the amygdala and the ventromedial prefrontal cortex. Using the Schedule 1 substance MDMA for this purpose is however controversial; animal studies have indicated that MDMA is neurotoxic, although no adverse effects on humans related to incidental use of MDMA in a controlled setting have been found. In conclusion, the data support that MDMA may be an efficient tool for treating PTSD, as well as safe and effective to use in a clinical context.

Hintergrund: In den letzten Jahren ist zunehmend deutlich geworden, dass Konsumenten von Ecstasy sich hinsichtlich Gebrauchsmuster und -kontext wie auch Spontanverlauf, Risiken und Konsequenzen von Konsumenten anderer legaler und illegaler Substanzen unterscheiden und möglicherweise eine recht eigenständige Gruppe darstellen. Diese eigenständige Gruppe wird im angelsächsischen Raum zum Teil auch als club drug user bezeichnet. Alarmierend waren die Vermutungen aus Voruntersuchungen, dass club drug-Konsumenten auch nach dem Konsum geringer Mengen von Ecstasy bemerkenswerte und möglicherweise überdauernde neurobiologische Veränderungen mit assoziierten kognitiven Beeinträchtigungen und Störungen aufzeigen. Dies stellt an sich eine mögliche Gefährdung der Konsumenten dar, zusätzlich wiederum können kognitive Veränderungen auch Einfluss nehmen auf den Verlauf des weiteren Suchtmittelkonsums und den Erfolg von Interventionen. Ziel: In der MAYA-Studie (Munich Assessment of Young Adults) werden an einer epidemiologischen Bevölkerungsstichprobe junger Erwachsener (Stichprobe A) sowie an einer klinischen Stichprobe von Ecstasy-Konsumenten (Stichprobe B) die Art und das Ausmaß kognitiver Störungen und Defizite in Abhängigkeit von Gebrauchsmustern und anderen Einflussfaktoren untersucht. Bei der Stichprobe A handelt es sich um ein Subsample der EDSPStudie. Zusätzlich zu den bereits erhobenen Charakterisierungen werden spezifische neurokognitive Maße (vor allem Aufmerksamkeit, Gedächtnis und exekutive Funktionen) und Fragebögen (Impulsivität, BDI, STAI etc.) erhoben. Die Probanden erhalten weiterhin ein Screening mit dem neu eingeführten Instrument WHO ASSIST (Alcohol, Smoking and Substance Involvement Screening Test). Wenn indiziert, wird eine Intervention im Sinne eines Motivational Enhancement durchgeführt. Initiale Auswirkungen werden in einem Telefoninterview sechs Wochen später überprüft. Ergebnisse: Die vorläufigen Ergebnisse beruhen auf einer Teilstichprobe. Insgesamt handelte es sich eher um Konsumenten mit geringgradigem bis moderaten Konsum. Dennoch ließen sich Unterschiede zwischen den Konsumentengruppen (Ecstasy, Cannabis, Alkohol) und den Nichtkonsumenten erkennen. Die Konsumenten von Ecstasy unterschieden sich am ausgeprägtesten von den Kontrollen. Die sich bisher abzeichnenden Unterschiede bei Aufmerksamkeit, Gedächtnis und exekutiven Funktionen scheinen bei der Gedächtnis- und Merkfähigkeit am ausgeprägtesten zu sein. Bei diesen vorläufigen Ergebnissen sind die Untersuchungsgruppen noch sehr heterogen und enthalten z.B. Probanden, die ihren Ecstasykonsum bereits wieder aufgegeben haben. / Introduction: In recent years it has become increasingly evident that ecstasy users represent a group distinct from users of other drugs. This is based on consumption patterns, context of use, development of use patterns and other factors. This group of users might be considered "club drug users", given the overlap, similarity of use patterns and consumptions within the class of club drugs. In recent neurobiological research, alarming results have been reported, indicating that persistent neurotoxic effects with concomitant cognitive problems may be induced by ecstasy consumption. Methods: In the Munich Assessment of Young Adults Study (MAYA) two samples of ecstasy users are investigated. Sample A is a sample of users drawn from an ongoing epidemiological longitudinal study of young adults in Munich. Sample B is an additional clinical sample. Both samples are characterized extensively and are neuropsychologically tested for attention, memory and executive functioning. A screening for harmful use is conducted with the German version of the WHO ASSIST (Alcohol, Smoking and Substance Involvement Screening Test). A Motivational Enhancement Intervention is applied when harmful use is detected. With a telephone interview the intervention's initial effect is assessed. Results: Initial results are based on a small sample. Use within the tested population is low to moderate. Still significant differences in attention, memory, and executive functioning could be detected with the current testing. Ecstasy users almost consistently showed the lowest cognitive functioning. The one difference is that ecstasy users were significantly faster in finger tapping and reaction. Note that the results are preliminary. The sample is heterogeneous, including both current and former users. Firmer results will be reported with the full sample size, allowing to further elucidate subgroups and interactions.

Objectives: To investigate the relationship between ecstasy use and mental disorders in a representative sample of adolescents and young adults. Method: Data for this investigation were drawn from the Early Developmental Stages of Psychopathology (EDSP) study, an epidemiological-longitudinal study in which 14-24 year-olds were examined prospectively over a period of about 4 years. Results are based on N=2462 participants who completed the whole study period and for whom drug use behavior could be determined. Results: (1) Ecstasy users, compared with non-users, were at significantly increased risk of DSM-IV substance related disorders, including alcohol use disorders (52.6 vs. 15.6%; OR=5.6, 95% CI=3.8-8.1). Further, ecstasy users also had a higher risk of alcohol use disorders, when compared with users of other illicit substances (52.6 vs. 40.3%; OR=1.7, 95% CI=1.1-2.4). (2) Ecstasy users had significantly higher rates for almost all DSM-IV mental disorders examined when compared with non-users (any non-substance use disorder: 68.7 vs. 44.5%; OR=3.1, 95% CI=2.1-4.4) and compared with users of other illicit drugs (any non substance use disorder: 68.7 vs. 55.5%; OR=1.8, 95% CI=1.2-2.6). (3) Ecstasy users also reported significantly higher rates of prescription medicine use, though they did not use more medical services than non-drug users. (4) Analyses of temporal patterns of ecstasy use and disorder onset revealed that the first use of ecstasy was secondary to the onset of DSM-IV mental disorders in the majority of cases. Still, subjects with mental disorders at baseline also showed a significantly increased risk for initiation of ecstasy use during the 4-year follow-up period. Conclusions: Care should be taken in cross sectional studies in interpreting mental disorder signs and symptoms merely as a consequence of ecstasy use, as ecstasy use might be associated with the use of multiple substances, and onset of mental disorder is more likely to precede rather than to follow use of ecstasy and related substances.